U.S., Dec. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07274254) titled 'Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease' on Nov. 19.
Brief Summary: The purpose of the study is to determine whether adding lidocaine to standard of care in pain management during severe vaso-occlusive crisis has an effect on the cumulative opioid consumption expressed as morphine milligram equivalent.
Study Start Date: March 01, 2026
Study Type: INTERVENTIONAL
Condition:
Vaso-occlusive Crisis of Sickle Cell Disease
Intervention:
DRUG: Lidocain
Lidocaine hydrochloride 20 mg/mL, solution, 20 mL ampoule for IV administration (25 ampoules) Administration : parenteral route on peripheral or ce...